Eclipse Bioinnovations Acquires Terrain Bio to Build an End-to-End AI Platform for RNA Therapeutics
The company announced it has acquired Terrain Bio, a techbio startup known for its AI/ML-driven RNA design and manufacturing analytics. The deal accelerates Eclipsebio’s push to deliver a fully integrated, data-first platform that supports RNA therapeutics from early design through manufacturing and validation—an increasingly urgent need as RNA-based medicines expand beyond vaccines into more complex therapeutic modalities.
